Laborde Carlos M, Castro-Santos Patricia, Díaz-Peña Roberto
Dreamgenics, 33010 Oviedo, Spain.
Faculty of Health Sciences, Universidad Autónoma de Chile, Talca 3460000, Chile.
J Pers Med. 2020 Oct 30;10(4):202. doi: 10.3390/jpm10040202.
Rheumatoid arthritis (RA) is a multifactorial, inflammatory and progressive autoimmune disease that affects approximately 1% of the population worldwide. RA primarily involves the joints and causes local inflammation and cartilage destruction. Immediate and effective therapies are crucial to control inflammation and prevent deterioration, functional disability and unfavourable progression in RA patients. Thus, early diagnosis is critical to prevent joint damage and physical disability, increasing the chance of achieving remission. A large number of biomarkers have been investigated in RA, although only a few have made it through the discovery and validation phases and reached the clinic. The single biomarker approach mostly used in clinical laboratories is not sufficiently accurate due to its low sensitivity and specificity. Multiplex immunoassays could provide a more complete picture of the disease and the pathways involved. In this review, we discuss the latest proposed protein biomarkers and the advantages of using protein panels for the clinical management of RA. Simultaneous analysis of multiple proteins could yield biomarker signatures of RA subtypes to enable patients to benefit from personalized medicine.
类风湿性关节炎（RA）是一种多因素、炎症性和进行性自身免疫性疾病，全球约1%的人口受其影响。RA主要累及关节，导致局部炎症和软骨破坏。及时有效的治疗对于控制炎症、预防RA患者病情恶化、功能残疾和不良进展至关重要。因此，早期诊断对于预防关节损伤和身体残疾、增加实现缓解的机会至关重要。在RA中已经研究了大量生物标志物，尽管只有少数生物标志物通过了发现和验证阶段并进入临床。临床实验室大多采用的单一生物标志物方法由于其低敏感性和特异性而不够准确。多重免疫测定可以提供更全面的疾病及相关途径信息。在本综述中，我们讨论了最新提出的蛋白质生物标志物以及使用蛋白质组学进行RA临床管理的优势。同时分析多种蛋白质可以产生RA亚型的生物标志物特征，使患者能够从个性化医疗中受益。
